Parkinson's disease (PD) is characterized by the degeneration of dopaminergic (DA) neurons constituting the nigrostriatal pathway. Neuroinflammation, related to microglial activation, plays an important role in this process. Exploration of animal models of PD using neuroimaging modalities allows to better understand the pathophysiology of the disease. Here, we fully explored a moderate lesion model in the rat in which 6-hydroxydopamine was unilaterally delivered in three sites along the striatum. The degenerative process was assessed through in vivo Positron Emission Tomography (PET) imaging and in vitro autoradiographic quantitation of the striatal dopamine transporter (DAT) and immunostaining of tyrosine hydroxylase (TH). The microglial activation was studied through in vitro autoradiographic quantitation of the 18 kDa translocator protein (TSPO) in the striatum and CD11b staining in the SN. In addition, a targeted metabolomics exploration was performed in both these structures using mass spectrometry coupled to HPLC. Our results showed a reproducible decrease in the striatal DAT density associated with a reduction in the number of TH-positive cells in the SN and striatum, reflecting a robust moderate degeneration of nigrostriatal DA neurons. In addition, we observed strong microglia activation in both the striatum and SN ipsilateral to the lesion, highlighting that this moderate degeneration of DA neurons was associated with a marked neuroinflammation. Our metabolomics studies revealed alterations of specific metabolites and metabolic pathways such as carnitine, arginine/proline, and histidine metabolisms. These results bring new insights in the PD mechanism knowledge and new potential targets for future therapeutic strategies.
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| INTRODUC TION
Parkinson's Disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and affects approximately 4.5 million people worldwide, with that number estimated to double by 2030 (Nasrallah & Dubroff, 2013) . PD is mainly characterized by the gradual loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), leading to dopamine depletion in the striatum. These neurons constitute the nigrostriatal DA pathway which plays an essential role in the control of voluntary motor movement (Chinta & Andersen, 2005) . While 5% of PD cases are inherited, 95% have no apparent genetic etiology (referred to as "sporadic PD") (Dauer & Przedborski, 2003) .
Patients suffering from PD exhibit motor features that can be grouped under the acronym TRAP: Tremor at rest, Rigidity, Akinesia, and Postural instability (Jankovic, 2008) . Nowadays, it is widely accepted that PD is also characterized by non-motor symptoms such as sensory abnormalities, behavioral changes, sleep disturbances, and autonomic dysfunction (Pfeiffer, 2016) . Although several risks factors have been identified such as aging and long-term exposition to pesticides, the processes that lead to the loss of DA neurons are not yet fully understood.
Many postmortem brain imaging and fluid biomarker studies indicate that neuroinflammation is an important feature of PD (Poewe et al., 2017) . Neuroinflammation is mainly characterized by microglial activation which induces the release of a large group of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) that contribute to the degeneration of DA neurons (Wang et al., 2015) . Moreover, DA neurons in the SNpc are particularly susceptible to microglial-mediated neurotoxicity due to the high density of microglia in this brain area (Collins et al., 2012) . Consequently, targeting neuroinflammation constitutes a promising therapeutic strategy for PD.
Although all facets of PD are nearly impossible to model in animals (Vingill et al., 2017) , these models are invaluable tools to gain knowledge of mechanisms involved in the pathological process and to evaluate new therapeutic approaches. In this context, the recent development of noninvasive imaging methods in small animals gives the unique opportunity to follow at the same time a number of various parameters such as brain activity, neurotransmission, and neuroinflammation during the course of the disease, and the effects of potential treatments. In this field, positron emission tomography (PET) has already demonstrated its usefulness, particularly in 6-hydroxydopamine (6-OHDA) lesion models of PD in rodents (Casteels et al., 2008; Fricke et al., 2016; Molinet-Dronda et al., 2015) . Although these models have been well recognized and widely used, most use direct injections of the toxin into the SNpc or medial forebrain bundle (MFB), producing a rapid and massive (>90%) degeneration of DA neurons (Gubellini & Kachidian, 2015) that reflect late stages of PD (Glajch et al., 2012) . By contrast, administration of 6-OHDA in the striatum produces a progressive and moderate lesion corresponding to early stages of the disease (Deumens et al., 2002; Kirik et al., 1998) , appearing therefore better adapted for the evaluation of potential treatments. Several modalities of striatal 6-OHDA administration have already been described, using different doses and injection sites. The administration of low dose in three different sites of the rat striatum was recently shown to induce a stable and reliable moderate lesion as assessed by rotational behavior and number of intact dopaminergic cells (Penttinen et al., 2016) .
In this study, we fully characterized a close moderate 6-OHDA lesion model suitable for neuroimaging modalities, especially using PET. To this aim, we explored the degeneration of DA neurons by in vivo PET imaging with [
18 F]LBT-999, a dopamine transporter (DAT) tracer useful for PET human studies Ribeiro et al., 2017) . These imaging findings were compared to other characteristics of the model, such as the microglia activation and brain metabolome which were explored through in vitro analyses.
| MATERIAL S AND ME THODS

| Animals
All procedures were conducted in accordance with the European Community Council Directive 2010/63/EU for laboratory animal care and the experimental procedure was validated by the Regional Ethical Committee (Authorization N°00434.02). Experiments were carried out on adult male Wistar rats (Charles River, France) weighting 300 ± 5 g (n = 22) at the beginning of the experiments. Animals were housed in groups of two per cage in a temperature (21 ± 1°C) and humidity (55% ± 5%) controlled environment under a 12-h light/dark cycle, with food and water available ad libitum.
| 6-OHDA lesion
Twenty minutes before surgery, rats were injected intra-peritoneally with pargyline hydrochloride (50 mg/kg, Abcam, Paris, France) in order to prevent 6-OHDA oxidation by monoamine oxidase. Then, they were anesthetized with isoflurane (4%, 500 mL/min, Baxter, France), placed on a stereotaxic frame (Stoelting, Phymep, Paris, France) and maintained under isoflurane 2.5% (500 mL/min) during surgery. Body temperature was monitored and kept as constant as possible (37°C) using a thermal probe. Lesion was obtained by intrastriatal injection of 6-OHDA hydrochloride (Sigma-Aldrich, Saint-Quentin Fallavier, France). A total of 12 μg of 6-OHDA was administered in three areas of the right striatum (2 mg/mL in 0.01% ascorbic acid dissolved in saline, pH 4.5, i.e., 4 μg in 2 μL for each area) using a 25-μL Hamilton Gastight syringe (Hamilton, 
| Amphetamine-induced rotations test
At 13 days post-lesion, all rats received an intra-peritoneal injection of d-amphetamine sulfate (3 mg/kg) (Sigma-Aldrich, Saint-Quentin Fallavier, France) and were placed in automatic rotometer bowls (Imetronic, Pessac, France). Fifteen minutes after injection, the number of ipsilateral rotation was measured for 2 hr. Full rotation was determined as a complete, uninterrupted 360° turn.
| PET imaging study
| Radiotracer preparation
No-carrier added [ 18 F]LBT-999 was prepared as previously described (Sérrière et al., 2014) and obtained with a radiochemical purity >98% and a specific activity comprised between 30 and 190 GBq/μmol.
| PET imaging and data analyses
PET imaging was performed at 14 days post-lesion (n = 8) using a microPET/CT SuperArgus system (Sedecal, Madrid, Spain), according to a previously published method (Sérrière et al., 2014) . Before PET acquisition, a 5-min computed tomography scan was acquired for attenuation correction. A bolus injection of 37 MBq/300 g body weight of [ 18 F]LBT-999 in saline was administered into the tail vein of anesthetized rats, and acquisition lasted 50 min. PET images were analyzed with the region of interests (ROIs) for the left striatum (Contralateral-Striatum (C-ST),
i.e., non-lesioned striatum), right striatum (Ipsilateral-Striatum (I-ST), i.e., lesioned striatum), and Cerebellum (CE). In this study, the Standard Uptake Value ratio (SUVr) was used as quantitative criterion. All SUVrs were calculated using the CE as reference region.
| Metabolomics study
| Brain tissue preparation
After PET imaging, at 14 days post-lesion, animals (n = 8) were killed by decapitation and the following four ROIs were removed: C-ST, I-ST, contralateral-substantia nigra (C-SN), and ipsilateral-substantia nigra (I-SN). As previously described by Diémé et al. (2017) , samples were weighted and lyophilized for 48 hr in a FreeZone ® Freeze Dry Systems 4.5 I Benchtop lyophilizer (Labcono ® , Kansas City, Mo, USA) and milled to a fine powder (from 40 mg of fresh tissue for striatum and 6 mg for SN, around 10 and 1 mg of powder were obtained for each structure, respectively). For the striatum, 3 mg of each lyophilized sample was weighed for further extraction while for the SN, the entire lyophilized tissue was extracted. After lyophilization, samples were extracted twice with 1.5 mL of acetonitrile/milliQ water (1/1). After centrifugation, liquid phases were isolated and evaporated. Dried residues were kept at −80°C before liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis.
F I G U R E 1 Stereotaxic coordinates of 6-OHDA injection in the right striatum (delimited by a red line) according to the rat brain Atlas of Paxinos and Watson (2009) . Abbreviation: 6-OHDA (6-hydroxydopamine)
| LC-HRMS analysis
The dried residues were reconstituted in 150 μL MeOH/H 2 O (1/1). As previously described by Diémé et al. (2017) , LC-HRMS analysis was performed using a UPLC Ultimate 3000 system (Dionex, Sunnyvale, Calif., USA), coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Germany) and operating in positive (ESI+) and negative (ESI-) electrospray ionization modes. Chromatography was carried out with a Phenomenex Kinetex 1.7 μm XB-C18 (150 mm × 2.10 mm) and 100 Å UHPLC column. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in methanol. The gradient operated at a flow rate of 0.4 mL/min over a run time of 30 min.
During the full-scan acquisition, which ranged from 60 to 900 m/z, the instrument operated at 70 000 resolution (m/z = 200). In order to equilibrate the chromatographic system, 20 quality controls (QCs) (obtained by mixing an equal volume of all samples) were injected. The sequence of samples for analysis was randomized and QCs were analyzed every 10 samples and at the end of the run. Data quality was checked based on QCs results by principal component analysis PCA.
| Targeted data processing
A library of standard compounds (Mass Spectroscopy Metabolite Library of standards MS ML®, IROA technologies) was analyzed with the same gradient of mobile phases and in the same conditions as those used to analyze our samples. The annotation of selected features was validated from retention time, and high-resolution mass molecular (m/z) . Targeted molecules were selected and integrated using Xcalibur 2.2 (Thermo Fisher Scientific, San Jose, CA). Each peak area was normalized to the dried mass of tissues. Coefficients of variation (CV) for QC samples were calculated. Only metabolites with high biological variability were selected and only metabolites with CV < 30% in the QCs and CV > 30% in the case where the biological variability (CV in samples) exceeded the analytical variability (CV in QCs).
| Autoradiographic and immunofluorescence analysis 2.6.1 | Brain tissue preparation
At 14 days post-lesion, rats (n = 14) were injected intra-peritoneally with an overdose of pentobarbital (60 mg/kg, Ceva Santé Animale, France) and transcardially perfused with cold sterile physiological water (250 mL per rat). The brain was then carefully removed, frozen at −35°C in an isopentane/dry ice mixture and stored at −80°C. Coronal brain sections (16-μm thick) were cut with a cryostat (CM3050S, Leica, Germany) at −20°C, collected on gelatinized slides and stored at −80°C until the experiments. Chalon et al. (1999) and obtained with a specific activity of 95 TBq/mmol. [ 3 H]DPA-714 was prepared according to Damont et al. (2015) and obtained with a specific activity of 2.01 TBq/mmol. Six brain sections per animal were studied. Brain sections were allowed to equilibrate at room temperature (RT) for 3 hr and 
| Autoradiography
| Immunofluorescence
For immunostaining of tyrosine hydroxylase (TH) in both the striatum and SN and microglia using CD11b in the SN, brain sections were post-fixed (using PFA 4%, 30 min) and blocked (using 5% normal goat serum, 0.3% Triton 100X in 0.1 M PBS, 3 hr at RT). Then, sections were incubated with anti-TH (1/1000; Abcam ab112, Paris, France) or an anti-CD11b (1/500; Merck Millipore CBL1512, Saint-Quentin en Yvelines, France) primary antibody overnight at 4°C followed by an incubation with a fluorescence-coupled secondary antibody for 1 hr at RT: either a goat anti-rabbit (Alexa 555; Abcam ab150086, Paris, France) or a goat anti-mouse (Alexa 488; Abcam ab150113) at a dilution of 1/500. Finally, nuclei were counterstained using 4'-6-diamino-2-phenylindole (DAPI) (1/10000; Sigma-Aldrich D9542, Saint-Quentin Fallavier, France) and sections were mounted using a mounting medium for fluorescent staining (Abcam Ab103746, Paris, France). TH and CD11b labeling were visualized using a Leica DM5500 B fluorescence microscope (Germany) with an ORCA-R2 camera (Hamamatsu Photonics, Massy, France).
Pictures were analyzed using ImageJ Software. For TH labeling in the striatum, the percentage of the area stained by TH was automatically measured in each ROI in both the C-ST and I-ST. In the SN, the number of TH positive cells was manually counted in the C-SN and the I-SN.
For CD11b labeling, a ROI of SN was designed for each section in both C-SN and I-SN. In these ROIs, the percentage of the area stained by CD11b was automatically measured.
| Statistical analysis
All results were expressed as mean ± standard error mean (SEM). For PET imaging, autoradiographic and immunofluorescence analysis, comparisons between C-ST and I-ST, and between C-SN and I-SN were performed using the Wilcoxon test two-tailed. Statistical analyses were carried out with the GraphPad Prism software version 6. For the metabolomics study, multivariate analysis was performed using the Simca-P + -13 software (Umetrics, Umea, Sweden 
| RE SULTS
| Amphetamine-induced rotations test
The amphetamine-induced rotations test was performed at 13 days post-lesion. All animals (n = 22) displayed a turning behavior, with an average of 8.73 ± 0.67 ipsilateral rotations per minute, demonstrating the 6-OHDA lesion.
| PET imaging study
PET imaging of DAT with [ 18 F]LBT-999 (n = 7, 1 rat was excluded due to an injection problem) was performed at 14 days post-lesion. PET brain 
| Metabolomics study
Analyses of the metabolome of the striatum and SN were performed by LC-HRMS targeted analysis. The score plots resulting from the OPLS-DA for the striatum (n = 8) and the PLS-DA for the SN (n = 7, 1 sample was inoperable because of extraction problem) are represented in Figure 3a and b, respectively. Each model was defined by a descriptive value (R 2 Y = robustness of the model) and a predictive value (Q 2 = predictive capacity of the model). R 2 Y was high for both the striatum and SN (0.90 and 0.84, respectively) but Q 2 was lower for the SN than for the striatum (0.53 and 0.78, respectively). However, a Q 2 ≥ 0.4 was considered as acceptable for a biological model (Worley & Powers, 2013) .
Both OPLS-DA and PLS-DA showed a clear separation between the cerebral structures originating from the ipsilateral and contralateral hemi- (Table 1) C-ST). For the SN, only one metabolite was identified: glucose-6-phosphate (lower in I-SN vs. C-SN). The metabolite pathway analysis showed a highly significant alteration of the arginine and proline metabolism both in the striatum and SN (supplementary Table 1 & Table 2 ). The Venn diagram of this pathway highlighted specific alteration according to the brain structure (supplementary Figure 1) . In addition, in the SN highly significant modifications were found in aminoacyl-tRNA biosynthesis and histidine metabolism (supplementary Table 2 ).
spheres (I-ST vs. C-ST and I-SN vs. C-SN). Multivariate and univariate analysis
| Autoradiographic and immunofluorescence analysis
The DAT density was evaluated on coronal brain sections by [ 125 I]PE2I binding (n = 14) as illustrated in Figure 4a . As shown in Figure 4b quantitative measurements showed that the area occupied by CD11b staining was statistically significantly higher (by 2690% ± 330%) in the I-SN compared to the C-SN (10.64 ± 0.83 vs. 0.44% ± 0.04%, respectively, p = 0.0001).
| D ISCUSS I ON
Since current PD treatments do not provide adequate neuroprotection and are unable to slow down the progression of PD, there is an urgent need to reach novel therapeutic strategies (Tarazi et al., 2014) . In this context, the development and characterization of animal models of PD enabling the evaluation of these treatments, especially using neuroimaging modalities is paramount. Toxic models of PD are based on systemic or local administration of neurotoxins which induce degeneration of the nigrostriatal DA system (Blandini et al., 2008) . Among these models, the injection of 6-OHDA (Ungerstedt, 1968) in the striatum produces a specific retrograde, progressive, and moderate lesion of nigrostriatal DA neurons. This type of lesion mimicking early stages of PD appears more adapted than total lesions for the evaluation of potential neuroprotective strategies. However, the extension of the lesion depends on several experimental parameters including the total dose of injected toxin and the site of injection (Kirik et al., 1998) . On this basis, we used a model in which the 6-OHDA is unilaterally delivered in three sites in the striatum, in order to achieve a moderate and stable lesion along the structure. Our experiments were conducted at 14 days post-lesion, as it is known that the intra-striatal injection of 6-OHDA induces the degeneration of presynaptic nerve terminals within first days of injection, followed by a loss of dopaminergic cell bodies in the SN reaching a stable level from 2 weeks (Duty & Jenner, 2011) . We first assessed the rotational behavior of lesioned rats following amphetamine administration, which reflects the intensity of striatal dopamine depletion (Iancu et al., 2005; Tronci et al., 2012) and observed reproducible results among animals, indicative of a stable and reliable lesion. This observation was confirmed through direct in vivo evaluation of the striatal DAT using PET imaging, which provides assessment of dopaminergic nerve terminals (Brooks & Pavese, 2011; Tatsch & Poepperl, 2013) . For this aim, we used the [ 18 F]LBT-999, a selective radioligand of DAT used as promising tracer in clinical research , which has proven its usefulness in 6-OHDA-lesioned rats to quantitate the degree of lesion (Grealish et al., 2014; Serriere et al. 2015) . Accumulation of [
18 F]LBT-999 in the lesioned striatum was significantly lower than in the non-lesioned tissue, demonstrating a reproducible decrease in the DAT density reflecting the moderate (i.e., 70%) intensity of the lesion. This finding was in agreement with the significant dopamine depletion that we measured in the ipsilateral striatum using LC-HRMS targeted analysis. The intensity of the lesion as measured by PET imaging in the striatum was similar to that we obtained both using autoradiographic experiments with the in vitro specific radioligand of DAT [ 125 I]PE2I (Chalon et al., 1999) and using TH immunostaining.The ipsilateral SN showed a significant (60%) and reproducible reduction in the number of TH-positive cells, reflecting a depletion of DA neurons cell bodies. Overall, these findings demonstrated that this model was characterized by a reproducible and moderate lesion of DA neurons that can be assessed by PET imaging.
In association with the loss of DA neurons, activation of CNS immune cells such as microglia is typically observed in animal models of PD and in the SN of PD patients both in PET scan and postmortem studies (Thornton & Vink, 2012) . Microglial activation, one of the major hallmarks of neuroinflammation, induces the release of pro-inflammatory and cytotoxic molecules which contribute to DA neurons degeneration (Chao et al., 2014; Song & Kim, 2016) . At the same time, dying DA neurons release substances such as ATP which promote microglial activation (Saijo & Glass, 2011) . This bi-directional interaction between microglia and DA neurons is known to fuel the neurodegenerative process. In our model, we quantitated the striatal density of the 18 kDa TSPO which is considered as a sensitive marker of microglial activation (Chen & Guilarte, 2008; Rupprecht et al., 2010) using [ 3 H]DPA-714, a highly sensitive radioligand of TSPO which has demonstrated its usefulness to assess striatal microglial activation in a rat model of brain excitotoxicity (Foucault-Fruchard et al., 2017) . In parallel, microglial activation was assessed in the SN using immunostaining of CD11b, a surface protein which is overexpressed during activation of these cells (Roy et al., 2008) . We observed robust microglial activation in both the striatum and SN ipsilateral to the lesion, indicating that the partial degeneration of nigrostriatal DA neurons was associated with marked neuroinflammation, in agreement with previously obtained data (Maia et al., 2012) .
In order to better characterize the animal model, we performed a metabolomics analysis of brain structures involved in the nigrostriatal DA pathway, that is, the striatum and SN. To our knowledge, only a few metabolomics studies have been performed in preclinical models of PD (Gao et al., 2013; Zheng et al., 2016) . Dopamine depletion in the ipsilateral striatum was accompanied with a significant decrease in two metabolites associated with glucose pathways, glucose-1-phosphate in the ipsilateral striatum and glucose-6-phosphate in the ipsilateral SN.
These results are in agreement with [ 18 F]-FDG PET imaging studies performed in 6-OHDA models indicating an hypometabolism in the striatum and SN on the lesioned side (Casteels et al., 2008; Jang et al., 2012; Silva et al., 2013) . Interestingly, we observed a significant increase in free carnitine in the ipsilateral striatum but not in the SN. This increase could be an endogenous mechanism aimed at protecting dopaminergic nerve endings. In this context, L-carnitine and its acetylated derivative acetyl-L-carnitine have been shown to have anti-inflammatory properties when used as supplement in different animal models of neurodegenerative disorders (Afshin-Majd et al., 2017; Ferreira & McKenna, 2017; Sarkar et al., 2015; Silva-Adaya et al., 2008) . It is widely supposed that brain did not use fatty acids as energy substrates (Panov et al., 2014; Schönfeld and Reiser, 2013) . However, although this is true for neurons, the carnitine palmitoyl transferase (CPT) system, which allows the entry of long-chain fatty acids into the mitochondria for ß-oxidation, is functional in astrocytes (Jernberg et al., 2017; Panov et al., 2014) and in embryonic (Xie et al., 2016) and adult (Knobloch et al., 2017 ) neural stem cells. The role of carnitine in its anti-inflammatory or energetic functions remains to be elucidated in this model and may constitute for the future a starting point for the development of innovative therapeutic.
Beside single significant metabolites, the arginine and proline pathway was found to be altered both in the striatum and SN. Three metabolites involved in the polyamines biosynthesis were specifically modified in the striatum (L-Ornithine, Spermine, and Spermidine). Polyamines are ubiquitous molecules involved in apoptosis, cell division, and signal transduction (Handa et al., 2018 ) although its precise role remains to be elucidated. Accumulating evidences suggest that polyamines pathway is involved in the pathogenesis of PD (Gomes-Trolin et al., 2002; Lewandowski et al., 2010) . In the SN, a highly significant modification was found in aminoacyl-tRNA biosynthesis involving L-Phenylalanine and L-Tyrosine and in the histidine metabolism in agreement with the lesion. In this later pathway, an increased level of histamine was observed, as already reported PD subjects (Anichtchik et al., 2000; Rinne et al., 2002) . It can be pointed out that histamine can have neurotoxic effect (Liu et al., 2007; Rocha et al., 2016; Vizuete et al., 2000) . These results show that, alongside dopaminergic and energetic (glucose consumption) deregulation already known in PD, other alterations are observed (carnitine, polyamines, amino acids).
In conclusion, we extensively explored a robust 6-OHDA lesion model of PD in the rat which was characterized by a reproducible and moderate degeneration of DA neurons associated with a marked neuroinflammation, mimicking the early stages of the disease. The density of DA neurons was reliably quantitated in vivo by PET. Microglia activation was assessed herein using the TSPO ligand DPA-714, in vitro, but this ligand is also useful for clinical (Hamelin et al., 2016) Our original metabolomics studies highlighted the alteration of specific metabolites and metabolic pathways. It is not clear whether these modifications are deleterious or compensatory protective endogenous mechanisms consecutive to the lesion. In this context, further experiments will be necessary to evidence potential beneficial impact induced by the modulation of the carnitine, arginine/proline, and/or histidine metabolism. 
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